



- (51) **International Patent Classification:**
A61K 39/395 (2006.01) *C07K 16/24* (2006.01)
- (21) **International Application Number:**
PCT/US2024/061124
- (22) **International Filing Date:**
19 December 2024 (19.12.2024)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/612,905 20 December 2023 (20.12.2023) US
63/612,928 20 December 2023 (20.12.2023) US
- (71) **Applicants:** **ABBVIE INC.** [US/US]; 1 North Waukegan Road, North Chicago, IL 60064 (US). **ABBVIE DEUTSCHLAND GMBH & CO. KG** [DE/DE]; Mainzer Str. 81, 65189 Wiesbaden (DE).
- (72) **Inventors:** **WANG, Chen**; c/o AbbVie Inc., 1 North Waukegan Road, North Chicago, IL 60064 (US). **GAZA-BULSECO, Georgeen**; c/o AbbVie Inc., 1 North Waukegan Road, North Chicago, IL 60064 (US). **GERVAIS, Johanna Lindermuth**; c/o AbbVie Inc., 1 North Waukegan Road, North Chicago, IL 60064 (US). **WANG, Jie**; c/o AbbVie Inc., 1 North Waukegan Road, North Chicago, IL 60064 (US). **KNOCH, Eva-Maria**; c/o AbbVie Deutschland Gmbh & Co. KG, Knollstr. 50, 67061 Ludwigshafen (DE). **DEIMEL, Isabelle**; c/o AbbVie Deutsch-


land Gmbh & Co. KG, Knollstr. 50, 67061 Ludwigshafen (DE). **KALETA, Katharina**; c/o AbbVie Deutschland Gmbh & Co. KG, Knollstr. 50, 67061 Ludwigshafen (DE). **SIEDLER, Michael**; c/o AbbVie Deutschland Gmbh & Co. KG, Knollstr. 50, 67061 Ludwigshafen (DE). **MI, Xue**; c/o AbbVie Inc., 1 North Waukegan Road, North Chicago, IL 60064 (US). **YANG, Lihua**; c/o AbbVie Inc., 1 North Waukegan Road, North Chicago, IL 60064 (US).

(74) **Agent:** **LIANG, Bing** et al.; Jones Day, 250 Vesey Street, New York, NY 10281-1047 (US).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,

(54) **Title:** HIGH CONCENTRATION RISANKIZUMAB FORMULATIONS



(57) **Abstract:** The present disclosure relates to novel antibody formulations comprising risankizumab at a high concentration. The present disclosure further relates to methods of using such formulations for treating diseases (e.g., psoriasis and Crohn's disease).

[Continued on next page]

DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*